Every 8-K that Alto Ingredients, Inc. (ALTO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ALTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALTO filings page.
Alto Ingredients, Inc. entered into an At-The-Market Issuance Sales Agreement on August 5, 2026 with Craig-Hallum Capital Group LLC as designated sales agent, and The Benchmark Company, LLC and H.C. Wainwright & Co., LLC as additional agents. The program allows the company to offer and sell shares of common stock with an aggregate offering price of up to $50.0 million from time to time.
The shares will be issued under an effective Form S-3 shelf registration and a related prospectus supplement, with sales deemed “at the market offerings” under Rule 415. Alto expects to use any net proceeds for general corporate purposes, including working capital and capital expenditures. The agents will earn a 3.0% commission on gross proceeds, and the company is not obligated to sell, with no assurance that any shares will be sold before the agreement terminates.
Alto Ingredients reported much stronger results for the quarter ended June 30, 2026. Net sales were $245,698 thousand, up from $218,436 thousand a year earlier. Gross profit was $16.6 million, versus a gross loss in 2025, and Adjusted EBITDA was $23.7 million, both sharply higher year over year. Net income attributable to common stockholders was $11.4 million, or $0.15 per share, compared with a net loss of $11,312 thousand.
For the six months ended June 30, 2026, net sales were $470,378 thousand and net income attributable to common stockholders was $15,345 thousand, compared with a loss of $23,303 thousand in the prior-year period. Management noted this was the fourth consecutive quarter with positive gross profit, income from operations, net income and Adjusted EBITDA, supported by diversification across renewable fuels, specialty alcohols and essential ingredients and by earnings from Section 45Z tax credits. Transferable tax credits, net, contributed $5,112 thousand in Q2 and $9,012 thousand year to date. Cash and cash equivalents were $24.0 million at June 30, 2026, with borrowing availability of $106 million. The company also established a $50 million at-the-market equity program to provide additional financial flexibility for high-return organic projects.
Alto Ingredients, Inc. reported results from its June 23, 2026 annual meeting, where stockholders approved the new 2026 Omnibus Incentive Plan. The plan authorizes up to 7,000,000 shares for equity and cash-based awards and will run until June 23, 2036 unless ended earlier.
Shareholders also elected five directors, approved 2025 executive compensation in an advisory say-on-pay vote, and ratified RSM US LLP as independent registered public accounting firm for the year ending December 31, 2026.
Alto Ingredients, Inc. reported a strong turnaround for the quarter ended March 31, 2026. Net sales were $224.7 million, while gross profit reached $9.2 million, an $11.0 million improvement from the prior year’s loss. Net income was $4.0 million, or $0.05 per share, improving by $16.0 million versus Q1 2025. Adjusted EBITDA rose to $4.7 million, up $9.1 million year over year, helped by stronger export sales, higher crush margins and contributions from Section 45Z tax credits. Cash and cash equivalents were $20.3 million with borrowing availability of $94.3 million, and total stockholders’ equity was $249.9 million.
Alto Ingredients reported a strong turnaround in Q4 and full-year 2025 results. For Q4 2025, net income was $21.8M, compared with a loss of $41.7M a year earlier, and Adjusted EBITDA rose to $27.9M from a loss of $7.7M. Gross profit improved to $15.2M from a gross loss. For the year ended December 31, 2025, net income reached $13.3M versus a $59.0M loss in 2024, while Adjusted EBITDA increased to $44.7M from a loss of $8.5M. Net sales were $917.9M for 2025, modestly below 2024, but profitability improved across segments. Cash was $23.4M and total borrowing availability was $102M at year-end 2025.
Alto Ingredients, Inc. announced that on November 24, 2025, board member Jeremy T. Bezdek resigned from the company’s Board of Directors and from all board committees, effective the same day. The company stated that his resignation was not due to any disagreement with Alto Ingredients on its operations, policies, or practices. The filing does not describe any related changes to company strategy or governance beyond this board departure.
Alto Ingredients, Inc. filed a current report to share that it has released its financial results for the three and nine months ended September 30, 2025. On November 5, 2025, the company issued a press release detailing its results of operations and financial condition for this period. The press release is furnished as Exhibit 99.1 and incorporated by reference, but is not considered filed for liability purposes under the Exchange Act.
Alto Ingredients (Nasdaq:ALTO) filed an 8-K announcing it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common-stock bid price closed above $1.00 for 10 consecutive business days. Nasdaq’s letter dated June 23, 2025 states the deficiency is cured and the matter is closed.
The decision removes the immediate delisting threat and secures ALTO’s position on the Nasdaq Capital Market. No financial or operational updates were provided in the filing.
The Form 8-K filed by Alto Ingredients, Inc. (NASDAQ: ALTO) discloses the voting results of the company’s June 25, 2025 Annual Meeting of Stockholders (Item 5.07).
Key outcomes:
- Board elections: All six nominees—Bryon T. McGregor, Maria G. Gray, Gilbert E. Nathan, Dianne S. Nury, Jeremy T. Bezdek and Alan R. Tank—were elected by simple majorities; the highest support was 24.55 million votes for and the lowest was 21.61 million.
- Say-on-pay: 20.57 million votes for (73%) versus 7.27 million against; advisory compensation was approved.
- Say-on-pay frequency: A one-year frequency received 19.67 million votes, comfortably surpassing two-year (0.38 million) and three-year (6.80 million) alternatives; the board is expected to adopt an annual vote cadence.
- Auditor ratification: RSM US LLP re-appointed with 47.66 million votes for (93%), 2.35 million against, and 0.27 million abstentions.
No financial performance metrics, capital-allocation actions or strategic transactions were reported in this filing. The disclosure is routine governance information and is unlikely to materially affect the company’s valuation or near-term outlook.